Jacobs Levy Equity Management Inc. Reduces Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Jacobs Levy Equity Management Inc. trimmed its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 15.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,623,026 shares of the biotechnology company's stock after selling 642,074 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 2.26% of Ironwood Pharmaceuticals worth $16,050,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in IRWD. Hennion & Walsh Asset Management Inc. increased its position in shares of Ironwood Pharmaceuticals by 9.9% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 187,773 shares of the biotechnology company's stock worth $832,000 after purchasing an additional 16,962 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth approximately $53,000. Pacer Advisors Inc. increased its position in shares of Ironwood Pharmaceuticals by 4.0% during the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company's stock worth $51,967,000 after purchasing an additional 450,949 shares in the last quarter. EMC Capital Management boosted its stake in Ironwood Pharmaceuticals by 693.0% during the fourth quarter. EMC Capital Management now owns 23,893 shares of the biotechnology company's stock worth $106,000 after buying an additional 20,880 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Ironwood Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company's stock worth $150,000 after buying an additional 3,209 shares during the last quarter.

Ironwood Pharmaceuticals Trading Up 3.5%

IRWD opened at $0.73 on Tuesday. The stock's 50-day moving average price is $1.14 and its 200 day moving average price is $2.63. Ironwood Pharmaceuticals, Inc. has a 12-month low of $0.59 and a 12-month high of $7.11. The firm has a market cap of $118.74 million, a price-to-earnings ratio of -24.46 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm had revenue of $41.14 million for the quarter, compared to analyst estimates of $67.02 million. On average, research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Craig Hallum lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Wells Fargo & Company reissued an "equal weight" rating and set a $1.00 price objective (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Jefferies Financial Group reissued a "hold" rating and set a $0.70 price objective (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Leerink Partners decreased their price target on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating on the stock in a research note on Monday, April 14th. Finally, StockNews.com raised Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Seven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Ironwood Pharmaceuticals has a consensus rating of "Hold" and an average price target of $4.78.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.